ARDS, Human Clinical Trial
Official title:
PHASE II RANDOMIZED, INTERVENTION VERSUS NON- INTERVENTION, MULTI- CENTER STUDY OF THE EFFECTS OF THYROID HORMONE (T3) ON SAFETY/TOLERABILITY AND OXYGENATION IN SUBJECTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
T3 Therapy in ARDS- Phase 2 Randomized, Unblinded, Intervention versus Non- Intervention Trial. Enrollment 68 participants (50 treatment + 18 control). Purpose- To determine the safety and tolerability of T3 delivery into the lungs of ARDS patients, and to measure the effect of T3 on Oxygenation in ARDS patients. Study Drug- Liothyronine Sodium (T3), 50 mcg will be instilled twice daily via a catheter through the ETT into the airway in a total volume of 10 mL (T3+0.9% sodium chloride), over 5 days (10 total doses), or until extubation, whichever comes first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06444750 -
Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
|
||
| Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04274296 -
Advisory Lead ARDS Respirator Management
|
||
| Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
| Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
| Recruiting |
NCT03215316 -
Screening Expiratory Flow Limitation by Flow-time Curve
|
N/A | |
| Not yet recruiting |
NCT05061212 -
The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
|
||
| Not yet recruiting |
NCT04556864 -
Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
|
||
| Completed |
NCT05693051 -
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
|
||
| Recruiting |
NCT04174014 -
Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography
|
N/A | |
| Enrolling by invitation |
NCT06164639 -
Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
|
||
| Terminated |
NCT05384379 -
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
|
Early Phase 1 | |
| Completed |
NCT04375735 -
London's Exogenous Surfactant Study for COVID19
|
Phase 1/Phase 2 | |
| Completed |
NCT06224010 -
Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
|
||
| Not yet recruiting |
NCT04530188 -
Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS
|
Phase 3 | |
| Completed |
NCT03405038 -
Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
|
||
| Recruiting |
NCT05148026 -
Regional Citrate Anticoagulation for RRT During V-V ECMO
|
N/A | |
| Recruiting |
NCT04390360 -
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
|
N/A | |
| Completed |
NCT06197256 -
Cardiac Dysfunction in Critically Ill Covid-19 Patients
|
||
| Completed |
NCT04008225 -
Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System
|